Insulin response to glucose or glucagon in subclinical diabetes previously injected with tolbutamide. 1977

A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome

Thirty-one patients with subclinical diabetes, who showed diabetic or impaired glucose tolerance after treatment for diabetes, were investigated in order to clarify the abnormalities of insulin response in diabetes mellitus. These patients showed a delayed response of plasma insulin during oral glucose loading. In the tolbutamide-glucose test, in which glucose loading followed the intravenous tolbutamide injection at a 60-min interval, the insulin level at 90 min was significantly lowered in a group of 20 patients with subclinical diabetes. In the tolbutamide-glucagon test, in which 1 mg of glucagon was injected 60 min after tolbutamide injection, the maximal level of plasma insulin was significantly decreased in a group of 10 subclinical diabetes except for one patient. These results indicate that insulinogenesis and/or release of insulin were decreased even in subclinical diabetes, suggesting that such a defect in islet function might be one of the abnormalities in primary diabetes.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D011236 Prediabetic State The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2). Prediabetes,Prediabetic States,State, Prediabetic,States, Prediabetic
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014044 Tolbutamide A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290) Apo-Tolbutamide,Artosin,Diabetol,Diaval,Dolipol,Orabet,Orinase,Rastinon,Tolbutamid R.A.N.

Related Publications

A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
January 1986, Diabetes care,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
February 1982, The Tohoku journal of experimental medicine,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
September 1980, Diabetologia,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
April 1977, The Alabama journal of medical sciences,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
October 1972, Danish medical bulletin,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
February 1979, The American journal of physiology,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
November 1971, Comparative biochemistry and physiology. A, Comparative physiology,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
January 1966, Polskie Archiwum Medycyny Wewnetrznej,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
March 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
A Ohneda, and K Watanabe, and Y Maruhama, and H Itabashi, and K Horigome
June 1970, Metabolism: clinical and experimental,
Copied contents to your clipboard!